Correction to: A phase I/II study of gemcitabine during radiotherapy in children with newly diagnosed diffuse intrinsic pontine glioma (Journal of Neuro-Oncology, (2017), 135, 2, (307-315), 10.1007/s11060-017-2575-9)

Sophie E.M. Veldhuijzen van Zanten; Fatma E. El‑Khouly; Marc H.A. Jansen; Dewi P. Bakker; Esther Sanchez Aliaga; Cornelis J.A. Haasbeek; Nicole I. Wolf; C. Michel Zwaan; W. Peter Vandertop; Dannis G. van Vuurden; Gertjan J.L. Kaspers

doi:10.1007/s11060-017-2636-0

Correction to: A phase I/II study of gemcitabine during radiotherapy in children with newly diagnosed diffuse intrinsic pontine glioma (Journal of Neuro-Oncology, (2017), 135, 2, (307-315), 10.1007/s11060-017-2575-9)

Sophie E.M. Veldhuijzen van Zanten
, Fatma E. El‑Khouly
, Marc H.A. Jansen
, Dewi P. Bakker
, Esther Sanchez Aliaga
, Cornelis J.A. Haasbeek
, Nicole I. Wolf
, C. Michel Zwaan
, W. Peter Vandertop
, Dannis G. van Vuurden
, Gertjan J.L. Kaspers

Research output: Contribution to journal › Comment/debate

Abstract

In Table 2 of the original publication, there were errors in the baseline scores for the PedsQL TM 3.0 Cancer Module questionnaire, so a corrected version of Table 2 is shown in this erratum. In the subcategories of the PedsQL TM 3.0 Cancer Module questionnaire, nausea and fear of procedure did not score significantly lower after treatment compared to baseline. So, based on the corrected data in Table 2, there was no significant decrease in the total score of the cancer questionnaire, and this statement in the previous manuscript was incorrect.

Original language	English
Pages (from-to)	219-220
Number of pages	2
Journal	Journal of Neuro-Oncology
Volume	136
Issue number	1
DOIs	https://doi.org/10.1007/s11060-017-2636-0
Publication status	Published - 1 Jan 2018
Externally published	Yes

Access to Document

10.1007/s11060-017-2636-0

Fingerprint

Dive into the research topics of 'Correction to: A phase I/II study of gemcitabine during radiotherapy in children with newly diagnosed diffuse intrinsic pontine glioma (Journal of Neuro-Oncology, (2017), 135, 2, (307-315), 10.1007/s11060-017-2575-9)'. Together they form a unique fingerprint.

Cite this

Veldhuijzen van Zanten, S. E. M., El‑Khouly, F. E., Jansen, M. H. A., Bakker, D. P., Sanchez Aliaga, E., Haasbeek, C. J. A., Wolf, N. I., Zwaan, C. M., Vandertop, W. P., van Vuurden, D. G., & Kaspers, G. J. L. (2018). Correction to: A phase I/II study of gemcitabine during radiotherapy in children with newly diagnosed diffuse intrinsic pontine glioma (Journal of Neuro-Oncology, (2017), 135, 2, (307-315), 10.1007/s11060-017-2575-9). Journal of Neuro-Oncology, 136(1), 219-220. https://doi.org/10.1007/s11060-017-2636-0

Veldhuijzen van Zanten, Sophie E.M. ; El‑Khouly, Fatma E. ; Jansen, Marc H.A. et al. / Correction to : A phase I/II study of gemcitabine during radiotherapy in children with newly diagnosed diffuse intrinsic pontine glioma (Journal of Neuro-Oncology, (2017), 135, 2, (307-315), 10.1007/s11060-017-2575-9). In: Journal of Neuro-Oncology. 2018 ; Vol. 136, No. 1. pp. 219-220.

@article{0050f8df67b44492bfc77ad0c661afbe,

title = "Correction to: A phase I/II study of gemcitabine during radiotherapy in children with newly diagnosed diffuse intrinsic pontine glioma (Journal of Neuro-Oncology, (2017), 135, 2, (307-315), 10.1007/s11060-017-2575-9)",

abstract = "In Table 2 of the original publication, there were errors in the baseline scores for the PedsQL TM 3.0 Cancer Module questionnaire, so a corrected version of Table 2 is shown in this erratum. In the subcategories of the PedsQL TM 3.0 Cancer Module questionnaire, nausea and fear of procedure did not score significantly lower after treatment compared to baseline. So, based on the corrected data in Table 2, there was no significant decrease in the total score of the cancer questionnaire, and this statement in the previous manuscript was incorrect.",

author = "\{Veldhuijzen van Zanten\}, \{Sophie E.M.\} and El‑Khouly, \{Fatma E.\} and Jansen, \{Marc H.A.\} and Bakker, \{Dewi P.\} and \{Sanchez Aliaga\}, Esther and Haasbeek, \{Cornelis J.A.\} and Wolf, \{Nicole I.\} and Zwaan, \{C. Michel\} and Vandertop, \{W. Peter\} and \{van Vuurden\}, \{Dannis G.\} and Kaspers, \{Gertjan J.L.\}",

note = "Publisher Copyright: {\textcopyright} 2017, The Author(s).",

year = "2018",

month = jan,

day = "1",

doi = "10.1007/s11060-017-2636-0",

language = "English",

volume = "136",

pages = "219--220",

journal = "Journal of Neuro-Oncology",

issn = "0167-594X",

publisher = "Springer",

number = "1",

}

Veldhuijzen van Zanten, SEM, El‑Khouly, FE, Jansen, MHA, Bakker, DP, Sanchez Aliaga, E, Haasbeek, CJA, Wolf, NI, Zwaan, CM, Vandertop, WP, van Vuurden, DG & Kaspers, GJL 2018, 'Correction to: A phase I/II study of gemcitabine during radiotherapy in children with newly diagnosed diffuse intrinsic pontine glioma (Journal of Neuro-Oncology, (2017), 135, 2, (307-315), 10.1007/s11060-017-2575-9)', Journal of Neuro-Oncology, vol. 136, no. 1, pp. 219-220. https://doi.org/10.1007/s11060-017-2636-0

Correction to: A phase I/II study of gemcitabine during radiotherapy in children with newly diagnosed diffuse intrinsic pontine glioma (Journal of Neuro-Oncology, (2017), 135, 2, (307-315), 10.1007/s11060-017-2575-9). / Veldhuijzen van Zanten, Sophie E.M.; El‑Khouly, Fatma E.; Jansen, Marc H.A. et al.
In: Journal of Neuro-Oncology, Vol. 136, No. 1, 01.01.2018, p. 219-220.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Correction to

T2 - A phase I/II study of gemcitabine during radiotherapy in children with newly diagnosed diffuse intrinsic pontine glioma (Journal of Neuro-Oncology, (2017), 135, 2, (307-315), 10.1007/s11060-017-2575-9)

AU - Veldhuijzen van Zanten, Sophie E.M.

AU - El‑Khouly, Fatma E.

AU - Jansen, Marc H.A.

AU - Bakker, Dewi P.

AU - Sanchez Aliaga, Esther

AU - Haasbeek, Cornelis J.A.

AU - Wolf, Nicole I.

AU - Zwaan, C. Michel

AU - Vandertop, W. Peter

AU - van Vuurden, Dannis G.

AU - Kaspers, Gertjan J.L.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - In Table 2 of the original publication, there were errors in the baseline scores for the PedsQL TM 3.0 Cancer Module questionnaire, so a corrected version of Table 2 is shown in this erratum. In the subcategories of the PedsQL TM 3.0 Cancer Module questionnaire, nausea and fear of procedure did not score significantly lower after treatment compared to baseline. So, based on the corrected data in Table 2, there was no significant decrease in the total score of the cancer questionnaire, and this statement in the previous manuscript was incorrect.

AB - In Table 2 of the original publication, there were errors in the baseline scores for the PedsQL TM 3.0 Cancer Module questionnaire, so a corrected version of Table 2 is shown in this erratum. In the subcategories of the PedsQL TM 3.0 Cancer Module questionnaire, nausea and fear of procedure did not score significantly lower after treatment compared to baseline. So, based on the corrected data in Table 2, there was no significant decrease in the total score of the cancer questionnaire, and this statement in the previous manuscript was incorrect.

UR - https://www.scopus.com/pages/publications/85031936372

U2 - 10.1007/s11060-017-2636-0

DO - 10.1007/s11060-017-2636-0

M3 - Comment/debate

C2 - 29063425

SN - 0167-594X

VL - 136

SP - 219

EP - 220

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

IS - 1

ER -

Veldhuijzen van Zanten SEM, El‑Khouly FE, Jansen MHA, Bakker DP, Sanchez Aliaga E, Haasbeek CJA et al. Correction to: A phase I/II study of gemcitabine during radiotherapy in children with newly diagnosed diffuse intrinsic pontine glioma (Journal of Neuro-Oncology, (2017), 135, 2, (307-315), 10.1007/s11060-017-2575-9). Journal of Neuro-Oncology. 2018 Jan 1;136(1):219-220. doi: 10.1007/s11060-017-2636-0